Cantor Fitzgerald Remains a Buy on Disc Medicine (IRON)
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Disc Medicine yesterday and set a price target of $125.00. The company’s shares closed yesterday at $68.53.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Kluska is a 5-star analyst with an average return of 26.7% and a 49.23% success rate. Kluska covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Capricor Therapeutics, and Soleno Therapeutics.
Currently, the analyst consensus on Disc Medicine is a Strong Buy with an average price target of $97.67, a 42.52% upside from current levels. In a report released on May 11, Stifel Nicolaus also maintained a Buy rating on the stock with a $111.00 price target.
Based on Disc Medicine’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $63.5 million. In comparison, last year the company had a GAAP net loss of $34.09 million
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRON in relation to earlier this year. Most recently, in February 2026, Jean M. Franchi, the CFO of IRON sold 4,075.00 shares for a total of $256,154.50.
Read More on IRON:
